CLOs on the Move

Well and Company

www.wellandcompany.com

 
Well & Company™ is igniting a self care revolution, offering its community members a powerful opportunity to share daily strategies that confront significant health and lifestyle challenges including aging, weight gain, fatigue, sleeplessness, stress, and loneliness. We “Embrace the Day™,” through social selling with our engaging content, innovative products and inspired community.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Accugen Laboratories Inc

Accugen Laboratories Inc is a Willowbrook, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quincy Medical Group

Quincy Medical Group is a Quincy, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Rose Hill Assisted Living

Rose Hill Assisted Living is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Proliance Surgeons

Proliance Surgeons is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Seattle, WA. To find more information about Proliance Surgeons, please visit www.proliancesurgeons.com

Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte`s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte`s 6mm HAVs for AV access for performing hemodialysis was the first product candidate to receive the FDA`s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation, and the HAV technology received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.